180 related articles for article (PubMed ID: 31951548)
1. Mutant KRAS at the Heart of Tumor Immune Evasion.
van Maldegem F; Downward J
Immunity; 2020 Jan; 52(1):14-16. PubMed ID: 31951548
[TBL] [Abstract][Full Text] [Related]
2. Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy.
Boumelha J; Molina-Arcas M; Downward J
Clin Cancer Res; 2023 Dec; 29(24):5012-5020. PubMed ID: 37581538
[TBL] [Abstract][Full Text] [Related]
3. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.
Canon J; Rex K; Saiki AY; Mohr C; Cooke K; Bagal D; Gaida K; Holt T; Knutson CG; Koppada N; Lanman BA; Werner J; Rapaport AS; San Miguel T; Ortiz R; Osgood T; Sun JR; Zhu X; McCarter JD; Volak LP; Houk BE; Fakih MG; O'Neil BH; Price TJ; Falchook GS; Desai J; Kuo J; Govindan R; Hong DS; Ouyang W; Henary H; Arvedson T; Cee VJ; Lipford JR
Nature; 2019 Nov; 575(7781):217-223. PubMed ID: 31666701
[TBL] [Abstract][Full Text] [Related]
4. Targeting Mutant KRAS for Immunogenic Cell Death Induction.
Galluzzi L
Trends Pharmacol Sci; 2020 Jan; 41(1):1-3. PubMed ID: 31818506
[TBL] [Abstract][Full Text] [Related]
5. Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors.
Stites EC; Shaw AS
CPT Pharmacometrics Syst Pharmacol; 2018 May; 7(5):342-351. PubMed ID: 29484842
[TBL] [Abstract][Full Text] [Related]
6. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
Janes MR; Zhang J; Li LS; Hansen R; Peters U; Guo X; Chen Y; Babbar A; Firdaus SJ; Darjania L; Feng J; Chen JH; Li S; Li S; Long YO; Thach C; Liu Y; Zarieh A; Ely T; Kucharski JM; Kessler LV; Wu T; Yu K; Wang Y; Yao Y; Deng X; Zarrinkar PP; Brehmer D; Dhanak D; Lorenzi MV; Hu-Lowe D; Patricelli MP; Ren P; Liu Y
Cell; 2018 Jan; 172(3):578-589.e17. PubMed ID: 29373830
[TBL] [Abstract][Full Text] [Related]
7.
Skoulidis F; Goldberg ME; Greenawalt DM; Hellmann MD; Awad MM; Gainor JF; Schrock AB; Hartmaier RJ; Trabucco SE; Gay L; Ali SM; Elvin JA; Singal G; Ross JS; Fabrizio D; Szabo PM; Chang H; Sasson A; Srinivasan S; Kirov S; Szustakowski J; Vitazka P; Edwards R; Bufill JA; Sharma N; Ou SI; Peled N; Spigel DR; Rizvi H; Aguilar EJ; Carter BW; Erasmus J; Halpenny DF; Plodkowski AJ; Long NM; Nishino M; Denning WL; Galan-Cobo A; Hamdi H; Hirz T; Tong P; Wang J; Rodriguez-Canales J; Villalobos PA; Parra ER; Kalhor N; Sholl LM; Sauter JL; Jungbluth AA; Mino-Kenudson M; Azimi R; Elamin YY; Zhang J; Leonardi GC; Jiang F; Wong KK; Lee JJ; Papadimitrakopoulou VA; Wistuba II; Miller VA; Frampton GM; Wolchok JD; Shaw AT; Jänne PA; Stephens PJ; Rudin CM; Geese WJ; Albacker LA; Heymach JV
Cancer Discov; 2018 Jul; 8(7):822-835. PubMed ID: 29773717
[No Abstract] [Full Text] [Related]
8. Exploiting the therapeutic implications of KRAS inhibition on tumor immunity.
Molina-Arcas M; Downward J
Cancer Cell; 2024 Mar; 42(3):338-357. PubMed ID: 38471457
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic Modulation of the Tumor Immune Microenvironment to Potentiate Immune Checkpoint Blockade Therapy.
Menzel J; Black JC
Cancer Discov; 2020 Feb; 10(2):179-181. PubMed ID: 32024681
[TBL] [Abstract][Full Text] [Related]
10. Can the Help Match the Hype? KRAS
Klempner SJ; Hata AN
Cancer Discov; 2020 Jan; 10(1):20-22. PubMed ID: 31919120
[TBL] [Abstract][Full Text] [Related]
11. Newly Synthesized KRAS
Cancer Discov; 2020 Mar; 10(3):341. PubMed ID: 31953242
[No Abstract] [Full Text] [Related]
12. Drug Combinatorial Therapies for the Treatment of KRAS Mutated Lung Cancers.
He H; Xu C; Cheng Z; Qian X; Zheng L
Curr Top Med Chem; 2019; 19(23):2128-2142. PubMed ID: 31475900
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
[TBL] [Abstract][Full Text] [Related]
14. KRAS-Mutant non-small cell lung cancer: From biology to therapy.
Ferrer I; Zugazagoitia J; Herbertz S; John W; Paz-Ares L; Schmid-Bindert G
Lung Cancer; 2018 Oct; 124():53-64. PubMed ID: 30268480
[TBL] [Abstract][Full Text] [Related]
15. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Fiala O; Pesek M; Finek J; Benesova L; Belsanova B; Minarik M
Cancer Genet; 2013; 206(1-2):26-31. PubMed ID: 23313110
[TBL] [Abstract][Full Text] [Related]
16. Back to the Bench? MEK and ERK Inhibitors for the Treatment of KRAS Mutant Lung Adenocarcinoma.
Kohler J; Catalano M; Ambrogio C
Curr Med Chem; 2018 Feb; 25(5):558-574. PubMed ID: 28554329
[TBL] [Abstract][Full Text] [Related]
17. Synthetic Lethal Vulnerabilities in
Aguirre AJ; Hahn WC
Cold Spring Harb Perspect Med; 2018 Aug; 8(8):. PubMed ID: 29101114
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review.
Kim JH; Kim HS; Kim BJ
Oncotarget; 2017 Jul; 8(29):48248-48252. PubMed ID: 28525386
[TBL] [Abstract][Full Text] [Related]
19. KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma.
Chen N; Fang W; Lin Z; Peng P; Wang J; Zhan J; Hong S; Huang J; Liu L; Sheng J; Zhou T; Chen Y; Zhang H; Zhang L
Cancer Immunol Immunother; 2017 Sep; 66(9):1175-1187. PubMed ID: 28451792
[TBL] [Abstract][Full Text] [Related]
20. Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK.
Wang J; Hu K; Guo J; Cheng F; Lv J; Jiang W; Lu W; Liu J; Pang X; Liu M
Nat Commun; 2016 May; 7():11363. PubMed ID: 27193833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]